Skip to main content

Kristen Yen

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Kristen Yen

Soleno Therapeutics Inc reported in an 8-K filed May 18, 2026 that Kristen Yen resigned as Senior Vice President, Global Clinical Operations & Patient Advocacy, effective May 18, 2026. The proxy statement of Soleno Therapeutics Inc reports total compensation of $821,666 for Kristen Yen in fiscal 2021, including a base salary of $291,000. Disclosed compensation is on record for 3 fiscal years.

“each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer of the Company, in each case, effective as of the Effective Time.”
Soleno Therapeutics Inc Form 8-K, filed May 18, 2026 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Soleno Therapeutics Inc

    Proxy statement

    Start not stated–2026-05-18

Company network

Recorded roles and call appearances connecting this person to public companies.

Soleno Therapeutics Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 Soleno Therapeutics Inc $291,000 $821,666
2019 Soleno Therapeutics Inc $250,000 $336,636
2018 Soleno Therapeutics Inc $235,000 $332,699

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.